Table 2.
Characteristics of patients with polypoidal choroidal vasculopathy who had a maintained or recurred sub/intraretinal fluid after extending the aflibercept treatment interval from 1 month to 2 months
| Maintained | Recurred | P value | |
|---|---|---|---|
| N (eyes) | 27 (67.5 %) | 13 (32.5 %) | |
| Sex (male/female) | 18/9 | 9/4 | >.999a |
| Age (years) | 67.7 ± 9.6 | 65.6 ± 8.4 | .508b |
| Laterality (right/left) | 9/18 | 6/7 | .498a |
| Location of vascular lesion (eyes) | >.999a | ||
| Subfoveal | 13 | 6 | |
| Juxtafoveal | 3 | 2 | |
| Extrafoveal | 11 | 5 | |
| Area of branching vascular network (mm2) | 3.86 ± 4.88 | 2.41 ± 1.24 | .732b |
| Number of polyps | 3.3 (1–11) | 3.0 (1–28) | .632b |
| Size of the largest polypoidal lesion (μm) | 288.5 ± 101.4 | 280.7 ± 145.5 | .441b |
| Location of the polyp closest to the fovea | >.325a | ||
| Subfoveal | 0 | 1 | |
| Juxtafoveal | 9 | 3 | |
| Extrafoveal | 18 | 9 | |
| Central subfield macular thickness (μm) | 368.4 ± 104.6 | 358.5 ± 108.7 | .842b |
| Completely dry (eyes) | |||
| Month 3 | 19 (70.4 %) | 8 (61.5 %) | .721 a |
| Month 6 | 26 (96.3 %) | 0 (0 %) | <.001a |
| Month 12 | 21 (77.8 %) | 3 (23.1 %)c | <.001a |
| Visual acuity (letters) | |||
| Baseline | 54.3 ± 20.0 | 56.9 ± 14.2 | .670b |
| Month 3 | 66.1 ± 15.1 | 60.0 ± 15.2 | .276b |
| Month 6 | 69.5 ± 16.1 | 57.1 ± 15.1 | .019b |
| Month 12 | 68.3 ± 15.5 | 55.5 ± 13.9 | .018b |
| Visual acuity gain (letters) | |||
| Month 3 | 11.9 ± 14.5 | 3.1 ± 7.3 | .039b |
| Month 6 | 15.3 ± 15.5 | 0.2 ± 14.9 | .005b |
| Month 12 | 14.1 ± 18.5 | −1.5 ± 12.4 | .005b |
a indicates P value calculated with a Fisher’s exact test
b indicates P value calculated with a Mann–Whitney U test
cincludes one eye that underwent rescue photodynamic therapy